{"id":23136,"date":"2025-05-12T19:55:01","date_gmt":"2025-05-12T19:55:01","guid":{"rendered":"https:\/\/www.hotelsalepage.com\/feed\/cision-pr-newswire\/accuredit-therapeutics-to-present-at-the-2025-annual-meeting-of-the-american-society-of-gene-cell-therapy\/"},"modified":"2025-05-12T19:55:01","modified_gmt":"2025-05-12T19:55:01","slug":"accuredit-therapeutics-to-present-at-the-2025-annual-meeting-of-the-american-society-of-gene-cell-therapy","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=23136","title":{"rendered":"AccurEdit Therapeutics to present at the 2025 Annual Meeting of the American Society of Gene & Cell Therapy"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

SUZHOU, China<\/span><\/span>, May 12, 2025<\/span><\/span> \/PRNewswire\/ —\u00a0AccurEdit Therapeutics today announced that its three abstracts have been selected for presentation, including one oral presentation on ART001, at the upcoming American Society of Gene & Cell Therapy (ASGCT) 28th<\/sup>\u00a0Annual Meeting being held from May 13-17, 2025<\/span>, in New Orleans, LA<\/span>.<\/p>\n

\n<\/div>\n

ART001 is the only LNP-based in vivo<\/i> gene editing product that has cleared INDs in both the US and China<\/span>. It is currently in phase I\/IIa studies in China<\/span> and phase I study in the US.<\/p>\n

The two poster presentations focus on ART002 and ARTbase-A1\u2122, respectively. ART002 is AccurEdit Therapeutics’ second pipeline product that has achieved nearly 90% reduction in PCSK9 and 56% reduction in LDL-C on average in HeFH patients with critically high LDL-C baselines (>6 mM). ARTbase-A1\u2122\u00a0is AccurEdit Therapeutics’ solely-owned base editor platform that has recently been granted patents in China<\/span> and the US.\u00a0<\/p>\n

“We thank the organizing committee of ASGCT for the opportunity to present the latest data on our pipeline products with best-in-class potentials and novel gene-editing tools with industry-leading performances.” said Yongzhong Wang<\/span>, Ph.D., CEO of AccurEdit Therapeutics. “We look forward to meeting our peers and potential collaborators to discuss the exciting perspective of delivering more efficient, safe and affordable in vivo<\/i> gene therapeutics for our patients globally.”<\/p>\n

Oral Presentation Details<\/b><\/p>\n

Abstract Title:<\/b>\u00a0ART001: Development and Interim Clinical Outcomes of a CRISPR-Based In Vivo Gene-Editing Therapy for Hereditary ATTR
Oral Presentation Date\/Time:\u00a0<\/b>Friday, May 16, 2025<\/span> at 5:15 PM – 5:30 PM CT<\/span>
Room: <\/b>Room 393-396
Final Abstract Number: AMA434<\/b><\/p>\n

Poster Presentation Details<\/b><\/p>\n

Abstract Title:<\/b>\u00a0Efficacy and Safety of ART002, a Single-dose Gene Editing Therapy, in Patients with Severe Heterozygous Familial Hypercholesterolemia
Poster Session Date\/Time:<\/b> Tuesday, May 13, 2025<\/span> at 6:00 PM – 7:30 PM CT<\/span>
Room: <\/b>Poster Hall Hall I2
Final Abstract Number: AMA562<\/b><\/p>\n

Abstract Title:<\/b>\u00a0Engineering TadA-Derived Base Editors with Enhanced Potency and Safety for non-viral In Vivo Gene Editing<\/i>
Poster Session Date\/Time:\u00a0<\/b>Thursday, May 15, 2025<\/span> at 5:30 PM – 7:00 PM CT<\/span>
Room: <\/b>Poster Hall Hall I2
Final Abstract Number: AMA559<\/b><\/p>\n

About AccurEdit Therapeutics: <\/b><\/p>\n

AccurEdit Therapeutics, founded in 2021, focuses on developing in vivo gene editing technologies and therapeutics based on LNP (lipid nanoparticle) and other non-viral delivery systems. The company is dedicated to providing innovative one-time treatment solutions with cost advantages for patients worldwide.<\/p>\n

The company boasts a professional team with full-lifecycle experience in successful biologics development and has established the world’s first clinically validated, industry-grade, end-to-end in vivo gene editing platform. It has systematically built intellectual property portfolios for related technologies and products, including ARTbase-A1\u2122, a novel base editor that has been granted a U.S. patent.<\/p>\n

AccurEdit Therapeutics has developed a pipeline targeting genetic rare diseases and refractory common disorders. In August 2023<\/span>, its ATTR-targeted therapy ART001 became China’s<\/span> first LNP-delivered in vivo gene editing drug to enter human clinical trials. By August 2024<\/span>, ART001 further achieved another milestone as the first and only product of its kind in China<\/span> to receive U.S. FDA clinical trial approval. In February 2025<\/span>, ART002, targeting HeFH (PCSK9), emerged as the world’s first in vivo gene editing therapy to demonstrate therapeutic saturation in humans, effectively reducing LDL-C in patients with extremely high baseline levels. Both ART001 and ART002 have shown safety and efficacy data with the potential to become global best-in-class therapies.<\/p>\n

BD Contact: Accuredit@accuredit.com<\/a>
PR Contact: tingting.zhang@accuredit.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

SUZHOU, China<\/span><\/span>, May 12, 2025<\/span><\/span> \/PRNewswire\/ —\u00a0AccurEdit Therapeutics today announced that its three abstracts have been selected for presentation, including one oral presentation on ART001, at the upcoming American Society of Gene & Cell Therapy (ASGCT) 28th<\/sup>\u00a0Annual Meeting being held from May 13-17, 2025<\/span>, in New Orleans, LA<\/span>.<\/p>\n

\n<\/div>\n

ART001 is the only LNP-based in vivo<\/i> gene editing product that has cleared INDs in both the US and China<\/span>. It is currently in phase I\/IIa studies in China<\/span> and phase I study in the US.<\/p>\n

The two poster presentations focus on ART002 and ARTbase-A1\u2122, respectively. ART002 is AccurEdit Therapeutics’ second pipeline product that has achieved nearly 90% reduction in PCSK9 and 56% reduction in LDL-C on average in HeFH patients with critically high LDL-C baselines (>6 mM). ARTbase-A1\u2122\u00a0is AccurEdit Therapeutics’ solely-owned base editor platform that has recently been granted patents in China<\/span> and the US.\u00a0<\/p>\n

“We thank the organizing committee of ASGCT for the opportunity to present the latest data on our pipeline products with best-in-class potentials and novel gene-editing tools with industry-leading performances.” said Yongzhong Wang<\/span>, Ph.D., CEO of AccurEdit Therapeutics. “We look forward to meeting our peers and potential collaborators to discuss the exciting perspective of delivering more efficient, safe and affordable in vivo<\/i> gene therapeutics for our patients globally.”<\/p>\n

Oral Presentation Details<\/b><\/p>\n

Abstract Title:<\/b>\u00a0ART001: Development and Interim Clinical Outcomes of a CRISPR-Based In Vivo Gene-Editing Therapy for Hereditary ATTR
Oral Presentation Date\/Time:\u00a0<\/b>Friday, May 16, 2025<\/span> at 5:15 PM – 5:30 PM CT<\/span>
Room: <\/b>Room 393-396
Final Abstract Number: AMA434<\/b><\/p>\n

Poster Presentation Details<\/b><\/p>\n

Abstract Title:<\/b>\u00a0Efficacy and Safety of ART002, a Single-dose Gene Editing Therapy, in Patients with Severe Heterozygous Familial Hypercholesterolemia
Poster Session Date\/Time:<\/b> Tuesday, May 13, 2025<\/span> at 6:00 PM – 7:30 PM CT<\/span>
Room: <\/b>Poster Hall Hall I2
Final Abstract Number: AMA562<\/b><\/p>\n

Abstract Title:<\/b>\u00a0Engineering TadA-Derived Base Editors with Enhanced Potency and Safety for non-viral In Vivo Gene Editing<\/i>
Poster Session Date\/Time:\u00a0<\/b>Thursday, May 15, 2025<\/span> at 5:30 PM – 7:00 PM CT<\/span>
Room: <\/b>Poster Hall Hall I2
Final Abstract Number: AMA559<\/b><\/p>\n

About AccurEdit Therapeutics: <\/b><\/p>\n

AccurEdit Therapeutics, founded in 2021, focuses on developing in vivo gene editing technologies and therapeutics based on LNP (lipid nanoparticle) and other non-viral delivery systems. The company is dedicated to providing innovative one-time treatment solutions with cost advantages for patients worldwide.<\/p>\n

The company boasts a professional team with full-lifecycle experience in successful biologics development and has established the world’s first clinically validated, industry-grade, end-to-end in vivo gene editing platform. It has systematically built intellectual property portfolios for related technologies and products, including ARTbase-A1\u2122, a novel base editor that has been granted a U.S. patent.<\/p>\n

AccurEdit Therapeutics has developed a pipeline targeting genetic rare diseases and refractory common disorders. In August 2023<\/span>, its ATTR-targeted therapy ART001 became China’s<\/span> first LNP-delivered in vivo gene editing drug to enter human clinical trials. By August 2024<\/span>, ART001 further achieved another milestone as the first and only product of its kind in China<\/span> to receive U.S. FDA clinical trial approval. In February 2025<\/span>, ART002, targeting HeFH (PCSK9), emerged as the world’s first in vivo gene editing therapy to demonstrate therapeutic saturation in humans, effectively reducing LDL-C in patients with extremely high baseline levels. Both ART001 and ART002 have shown safety and efficacy data with the potential to become global best-in-class therapies.<\/p>\n

BD Contact: Accuredit@accuredit.com<\/a>
PR Contact: tingting.zhang@accuredit.com<\/a><\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-23136","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/23136","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23136"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/23136\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23136"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23136"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23136"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}